China Healthcare Weekly recap: Round 12 national GPO rollout; foreign investment action plan

Research evidence excerpt

China Healthcare Weekly recap: Round 12 national GPO rollout; foreign investment action plan

Figure 1: Our preferred healthcare stocks and upcoming potential catalysts

Our prefe rred hea lthcar e stocks a nd upcoming potent

ial c ataly sts

Source: UBS-S estimates

Figure 2: Weekly index change – healthcare subsector Figure 3: YTD index change – healthcare subsector

comparison (%) comparison (%)

%)

son (

mpari

or co on (%)

bsect mparis

re su tor co

lthca subsec

– hea hcare

ange healt

ex ch ange –

y ind dex ch

Weekl YTD in

Source: Wind, UBS-S. Note: Data as of 26 June 2026; calculation based on market Source: Wind, UBS-S. Note: Data as of 26 June 2026; calculation based on market

cap weighted average. cap weighted average.

Figure 4: Recent healthcare expert calls

Date UBS Expert Call Series: Topic Expert Link

Pulse check on healthcare sector Dr Jiang, Chairman of China Strategic Association for Medical Device

26/06/26 Replay

following anti-corruption policy Technology

China AI drug discovery

25/06/26 market trends Ms Han Xiaomei, Founder of Aelion Therapeutics, former FDA expert Replay

The expert has 25 years of experience in the biomedical research and

23/06/26 Pulse check on Biologics CDMO applications, and used to be in the senior roles in multiple global and Report

China leading biologics CDMO and biopharma

The expert has over 10 years in a senior role of a domestic association

How should Chinese biopharma

05/06/26 related to business development (BD) and innovative drug supporting Report

BD in the future?

policies

FDA Policy Risk on China Clinical

21/05/26 Dr Zhang, Co-Founder and Chief Strategy Officer of ClinChoice Report

Data

In vivo CAR-T intro and cell

12/05/26 Mr Kong, Director of Clinical Operations at Starna Therapeutics Report

therapy market update